Navigation Links
Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease

MIAMI, Nov. 12 /PRNewswire/ -- The Miami Jewish Home and Hospital, Berma Research Group, and Segal Institute for Clinical Research today announced that they are actively enrolling patients in the CONNECTION study, a Phase 3 clinical trial that is evaluating the safety and efficacy of the investigational drug Dimebon as a treatment for mild-to-moderate Alzheimer's disease.

According to new estimates from the Alzheimer's Association, more than 5 million people in the United States are living with Alzheimer's disease, a progressive, debilitating and deadly disease that destroys brain cells and affects areas of the brain involved in memory, cognition, judgment, language and behavior. As the baby boomer population ages, the incidence of Alzheimer's disease is expected to increase dramatically. Currently available therapies for Alzheimer's treat the symptoms with modest effect, and there is no evidence that these medications alter the course of the underlying disease process.

"New therapies are urgently needed to more effectively treat the symptoms of Alzheimer's disease," said Dr. Marc Agronin, director of mental health services at the Miami Jewish Home and Hospital and associate professor of psychiatry at the University of Miami Miller School of Medicine. "Results from a previous study of Dimebon in Alzheimer's disease were encouraging, and we look forward to further assessing Dimebon's promise in the fight against Alzheimer's disease in the CONNECTION study. We encourage local patients and caregivers to learn more about this trial."

About Dimebon

Dimebon is an investigational therapy in clinical development for the treatment of Alzheimer's disease. It targets Alzheimer's disease differently than currently available therapies. Mitochondria (a cell's primary source of energy) are the target of Dimebon's mechanism of action.

Medivation, Inc., the company developing Dimebon and sponsoring the CONNECTION study, previously announced efficacy and safety results from the first pivotal trial showing that Dimebon improved the clinical course of Alzheimer's disease. In that study, patients treated with Dimebon showed significant improvement over patients treated with placebo (sugar pill) in each of the five most important aspects of Alzheimer's: memory, thinking, behavior, activities of daily living (such as eating and hygiene) and overall function. These improvements were seen after as little as 12 weeks of treatment with Dimebon and were maintained over a full year of treatment. Dimebon was well tolerated throughout the one-year treatment period.

About the CONNECTION Study

The CONNECTION study will enroll 525 patients in the United States -- as well as sites in Europe and South America -- to test the effects of Dimebon in patients with mild-to-moderate Alzheimer's disease. The study will evaluate the impact of Dimebon on cognition (thinking and awareness), memory, daily functioning, behavior and the ability to care for oneself.

Patients age 50 and older who are not taking any other Alzheimer's prescription medications may be eligible for the six-month study. Patients will randomly be chosen to receive either Dimebon or placebo. After six months of treatment, all patients -- including those receiving placebo -- will be offered the opportunity to receive Dimebon in an extension trial.

For more information on eligibility and enrollment, patients and caregivers can contact:

Miami Jewish Home & Hospital: 305-514-8503,

Berma Research Group: 305-702-9453,

Segal Institute for Clinical Research: 1-877-SEGAL-88,

CONNECTION study: 1-877-888-6386,

SOURCE Miami Jewish Home & Hospital; Berma Research Group; SegalInstitute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
2. Miami Plastic Surgeon Offers Hope to Acne Scarred Patients
3. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami
4. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
7. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
8. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
9. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
10. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
11. Alzheimers Association Grant Furthers Successful Research at UMass Lowell
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology:
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):